LC-MS. The anticancer activity of the fourty-three new isatin derivatives against human T lymphocyte cells Jurkat was evaluated by MTT assay in vitro. SAR study suggested that the combination of 1-benzyl and 5-[trans-2-(methoxycarbonyl)ethen-1-yl] substitution greatly enhanced their cytotoxic activity. Among them, compound 2h was shown to have a significant cytotoxic activity with an IC50 value of
设计并合成了一系列新颖的二或三取代的靛红衍生物,以5–6的步骤合成,总产率为25–45%。它们的结构通过1 H NMR和13 C NMR以及LC-MS确认。体外MTT法检测了43种新的伊斯汀衍生物对人T淋巴细胞Jurkat的抗癌活性。SAR研究表明1-苄基和5- [反式-2-(甲氧羰基)乙烯-1-基]取代的组合大大增强了它们的细胞毒活性。其中,化合物2h被证明具有显着的细胞毒性活性,IC50值为0.03μM,比其母分子isatin高330倍以上。对细胞形态变化的研究和膜联蛋白-V / PI染色研究表明,化合物2h通过诱导凋亡来抑制Jurkat细胞的增殖。由于化合物2h诱导线粒体膜电位的耗散和caspase-3的激活,很明显,化合物2h通过线粒体的凋亡途径抑制Jurkat细胞的增殖。除此之外,化合物2h对许多其他肿瘤细胞具有抑制作用,并且仅显示出对人正常细胞的弱细胞毒性,这表明化合物2h 具有广泛的抗癌谱和对正常细胞的高安全性。
[EN] DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS<br/>[FR] MACROCYCLES DIAMIDES UTILISÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2016205482A1
公开(公告)日:2016-12-22
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
A process produces an aromatic compound by bringing an aromatic compound (B) into contact with molecular oxygen (C) in the presence of a catalyst (A) comprising at least one of (A1) a heteropolyacid and/or a salt thereof, and (A2) a mixture of oxoacids and/or salts thereof containing, as a whole, one of P and Si and at least one selected from V, Mo and W to thereby yield another aromatic compound (G) than the aromatic compound (B). The process can produce, for example, a corresponding aromatic hydroxy compound (G1) by allowing the aromatic compound (B) to react with the molecular oxygen (C) further in the presence of a reducing agent (D).